Key result
ECG machine-learning score outperforms low-voltage criteria for differentiating cardiac amyloidosis from HCM with ~0.94 AUC.
Why the study?
Differentiating cardiac amyloidosis from hypertrophic cardiomyopathy in patients with ventricular hypertrophy is clinically crucial yet challenging, and advanced diagnostic imaging is not universally available. Widely accessible electrocardiography may guide early diagnostic prioritisation using an interpretable machine-learning approach.
Does an interpretable ECG-based machine-learning score improve the differential diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy compared to the classical low-voltage ECG criterion in patients with ventricular hypertrophy?
Observational (n=161)
Does an interpretable ECG-based machine-learning score improve the differential diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy compared to the classical low-voltage ECG criterion in patients with ventricular hypertrophy?
An interpretable machine-learning score using three routine 12-lead ECG parameters accurately differentiates cardiac amyloidosis from hypertrophic cardiomyopathy, significantly outperforming traditional low-voltage criteria.
Background Differentiating cardiac amyloidosis (CA) from hypertrophic cardiomyopathy (HCM) in patients with ventricular hypertrophy is clinically crucial but often challenging. Advanced imaging techniques provide unique diagnostic information but are not universally available. Electrocardiography (ECG), a low-cost and widely accessible tool, may offer valuable information to guide early diagnostic prioritisation. Purpose To develop and validate an interpretable, ECG-based machine-learning approach to differentiate CA from HCM using automatically extracted morphological ECG features. Methods We retrospectively analysed digital 12-lead ECGs from 161 patients with ventricular hypertrophy (25 CA, 136 HCM). A total of 468 ECG morphological variables were automatically extracted using the Philips DXL algorithm. After preprocessing, dimensionality reduction, and correlation filtering, feature selection was performed using a gradient boosting machine (XGBoost) across 300 resampling iterations with class balancing. Selected features were incorporated into an interpretable logistic regression–based risk score. Model performance was assessed using Harrell’s bootstrap validation and compared with the classical low-voltage ECG criterion. Results Three ECG parameters consistently emerged as key discriminators: R-wave amplitude in lead I, R-wave amplitude in lead II, and ventricular activation time in lead II (table 1). The resulting ECG-based score demonstrated excellent discrimination between CA and HCM (bootstrap-corrected AUC 0.94; Brier score 0.055), significantly outperforming the classical low-voltage criterion (AUC 0.63; p<0.001). Model calibration was robust, and the score retained full interpretability and clinical applicability. Conclusion An interpretable ECG-based machine-learning score accurately differentiates cardiac amyloidosis from hypertrophic cardiomyopathy in patients with ventricular hypertrophy, outperforming traditional voltage-based criteria. This pragmatic approach may facilitate earlier diagnosis and optimise referral for advanced imaging, particularly in resource-limited settings.
No takes yet. Share an insight, caveat, or question.
Cecconi et al. (2026) conducted an observational in Ventricular hypertrophy (cardiac amyloidosis vs hypertrophic cardiomyopathy) (n=161). ECG-based machine-learning risk score vs. Classical low-voltage ECG criterion was evaluated on Diagnostic discrimination between cardiac amyloidosis and hypertrophic cardiomyopathy (AUC 0.94 vs 0.63, p=<0.001). An ECG-based machine-learning score differentiated cardiac amyloidosis from hypertrophic cardiomyopathy (AUC 0.94), outperforming the low-voltage criterion (AUC 0.63; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: